Guardant Health/$GH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Guardant Health
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Ticker
$GH
Sector
Primary listing
Employees
2,010
Headquarters
Website
Guardant Health Metrics
BasicAdvanced
$6.8B
-
-$3.35
1.45
-
Price and volume
Market cap
$6.8B
Beta
1.45
52-week high
$68.00
52-week low
$20.14
Average daily volume
2.7M
Financial strength
Current ratio
3.705
Quick ratio
2.739
Long term debt to equity
-428.144
Total debt to equity
-436.746
Interest coverage (TTM)
-150.23%
Profitability
EBITDA (TTM)
-419.117
Gross margin (TTM)
62.84%
Net profit margin (TTM)
-49.93%
Operating margin (TTM)
-55.55%
Effective tax rate (TTM)
-0.26%
Revenue per employee (TTM)
$410,000
Management effectiveness
Return on assets (TTM)
-19.57%
Return on equity (TTM)
269.51%
Valuation
Price to revenue (TTM)
8.177
Price to book
-22.33
Price to tangible book (TTM)
-21.68
Price to free cash flow (TTM)
-24.943
Free cash flow yield (TTM)
-4.01%
Free cash flow per share (TTM)
-2.197
Growth
Revenue change (TTM)
28.74%
Earnings per share change (TTM)
-18.10%
3-year revenue growth (CAGR)
26.64%
3-year earnings per share growth (CAGR)
-14.84%
What the Analysts think about Guardant Health
Analyst ratings (Buy, Hold, Sell) for Guardant Health stock.
Bulls say / Bears say
Guardant Health was found liable for $83.4 million in damages by a Delaware federal court for infringing patents owned by TwinStrand Biosciences and the University of Washington, putting the company at risk of significant litigation expenses and possible future obligations (Reuters).
The company’s legal offensive against Natera—claiming the rival stole thousands of confidential documents to develop competing cancer blood tests—reflects potential diversion of resources and executive focus away from core business activities (Reuters).
Guardant Health received almost $3 million in legal fees after a U.S. judge sanctioned its former law firm, Quinn Emanuel, for misleading actions in its lawsuit against Natera, highlighting both the financial and reputational impacts of extended legal disputes (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 29 Aug 2025.
Guardant Health Financial Performance
Revenues and expenses
Guardant Health Earnings Performance
Company profitability
Guardant Health News
AllArticlesVideos
Alex M. Azar II Joins Guardant Health Board of Directors
Business Wire18 hours ago
Guardant Health Expands Access to Shield CRC Blood Test to Senior Living Communities with LabFlorida Partnership
Business Wire5 days ago
Guardant Health Announces Partnership with PathGroup Bringing Shield Blood Test to 250+ Hospitals and Health Systems in 25 States
Business Wire1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Guardant Health stock?
Guardant Health (GH) has a market cap of $6.8B as of September 16, 2025.
What is the P/E ratio for Guardant Health stock?
The price to earnings (P/E) ratio for Guardant Health (GH) stock is 0 as of September 16, 2025.
Does Guardant Health stock pay dividends?
No, Guardant Health (GH) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next Guardant Health dividend payment date?
Guardant Health (GH) stock does not pay dividends to its shareholders.
What is the beta indicator for Guardant Health?
Guardant Health (GH) has a beta rating of 1.45. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.